ANGLE shares continue march higher after signing cancer trial agreement

ANGLE, the London-listed liquid biopsy company specialising in innovative circulating tumor cell (CTC) diagnostic solutions, continued to surge higher on Wednesday after inking a significant deal with global pharmaceutical giant Eisai Inc yesterday.

ANGLE shares were 12% higher at the time of writing on Wednesday.

- Advertisement -

In a groundbreaking pilot study valued at $250,000, ANGLE is set to provide CTC analysis using its cutting-edge Portrait HER2 assay. The focus of this study is to evaluate the HER2 (human epidermal growth factor receptor 2) status of breast cancer patients participating in a Phase II trial of the HER2 targeting antibody-drug conjugate (ADC) BB-1701.

The success of this pilot study holds the potential for numerous large-scale follow-up investigations, marking a potentially pivotal moment in cancer research and drug development.

ANGLE’s Portrait HER2 assay stands out for its ability to quantitatively assess both HER2 protein expression (via IF) and HER2/neu gene amplification (via FISH).

This dual-pronged approach is crucial in identifying breast cancer patients who could benefit from anti-HER2 ADC treatment. Notably, HER2-low breast cancer, comprising 55% of all breast cancer cases, represents a significant portion of the market.

- Advertisement -

Analysts predict that the global HER2+ breast cancer ADC market is poised to reach a staggering US $3.3 billion per annum by 2030. With the market expanding into HER2-low patients, ANGLE’s strategic move to develop a quantitative HER2 assay becomes even more pivotal. This assay allows for the precise stratification of patient populations throughout the treatment pathway, considering that HER2 status can dynamically change over time.

Latest News

Subscribe to the UK Investor Magazine email newsletter

Register for our free email newsletter and receive the latest investment news, podcasts, event information and offers.

More Articles Like This

Tagdiv Cloud library - template content.